Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

Research output: Contribution to journalComment/debateResearchpeer-review

  1. Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply

    Research output: Contribution to journalComment/debateResearchpeer-review

View graph of relations
Original languageEnglish
JournalLancet Oncology
Volume21
Issue number2
Pages (from-to)193-194
Number of pages2
ISSN1470-2045
DOIs
Publication statusPublished - Feb 2020

    Research areas

  • Benzamides, Carcinoma, Non-Small-Cell Lung, Humans, Indazoles, Lung Neoplasms, Protein-Tyrosine Kinases, Proto-Oncogene Proteins

ID: 59523149